SynthesisFrontiers in immunology2026
PD-1/PD-L1 inhibitors plus chemotherapy as first-line therapy for advanced or metastatic endometrial cancer: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors combined with chemotherapy as first-line treatment for advanced or metastatic endometrial cancer. Methods: A systematic literature search was conducted in PubMed, Embase, Web of Science, the Cochrane Library, and ClinicalTrials.gov from inception to November 26, 2025. Meta-analyses were performed to pool outcomes including progression-free survival, overall survival, objective response rate, complete response, partial response, stable disease, progressive disease, and treatment-related adverse events. Results: Ten randomized controlled trials encompassing 4,052 patients were included (combination arm: n=2,109; chemotherapy-alone arm: n=1,943). Compared with chemotherapy alone, the addition of PD-1/PD-L1 inhibitors significantly prolonged median overall survival (43.7 vs. 29.1 months) and median progression-free survival (14.6 vs. 10.2 months). The relative risks (RR) for efficacy endpoints were as follows: complete response, 1.60 (95% CI: 1.25-2.05); partial response, 0.99 (95% CI: 0.88-1.12); stable disease, 0.68 (95% CI: 0.54-0.86); progressive disease, 0.69 (95% CI: 0.45-1.06); and objective response rate, 1.10 (95% CI: 1.02-1.18). The most common treatment-related adverse events were fatigue, alopecia, nausea, peripheral neuropathy, anemia, arthralgia, constipation, and diarrhea. Conclusion: The combination of PD-1/PD-L1 inhibitors and chemotherapy significantly improves progression-free survival and overall survival in patients with advanced or metastatic endometrial cancer, with the significant OS benefit in dMMR; PFS benefit but no OS benefit in pMMR. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD420251271038.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.